The goal of the Tissue Core is to provide investigators in the Pancreas SPORE with high quality patient data, DNA, RNA, serum, circulating tumor cells, and pancreas tissues from pancreatic cancer patients, and to make these resources available for future studies. The activities of the Tissue Core will be overseen under the combined leadership of Dr. W. Lingle, Director of the TACMA and Co-Director of the BAP Shared Resources of the Mayo Clinic Cancer Center, and Dr. T. Smyrk, anatomic pathologist. The activities of the Tissue Core will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible in the materials that are provided. The acquisition of human tissue and subsequent cellular/molecular analysis of that tissue within the context of pathology and patient data are key to many laboratory-based studies of cancer. The Mayo Clinic has a strong tradition of ethically sound support of research that links tissue acquisition and patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. The Tissue and Cell Molecular Analysis (TACMA) Shared Resource of the Mayo Clinic Cancer Center is a resource of expertise and service for immunohistochemistry, laser capture microdissection, tissue microarray preparation, and digital imaging. Likewise, the Biospecimen Accessioning and Processing (BAP) Shared Resource of the Mayo Clinic Cancer Center is the primary site of accessioning and standardized processing of blood, frozen tissue, and other non-paraffin embedded specimens collected explicitly for research. New methodologies for biospecimen collection, processing, and analysis will be developed in the Tissue Core. These methodologies will be shared with other Mayo SPORE Tissue Cores and integrated with services offered by the BAP and TACMA Shared Resources. Tissue Core activities will be closely coordinated with the newly formed Clinical Research Core and with the Biostatistics Core to provide seamless linkage of clinical annotations with research biospecimens. Core D will be integrated with the existing tissue-oriented Cancer Center shared resources and the other scientific Cores in this SPORE in order to provide a coordinated, centralized, dedicated program for standardized collection, accessioning, processing, and evaluation of biospecimens and patient data from pancreatic cancer patients. Furthermore, the Tissue Core will make biospecimens collected for this SPORE available to the pancreas cancer research community in order to stimulate translational research with the goal of improving prevention and treatment of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA102701-10W1
Application #
8719566
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
2013-09-12
Project End
2014-08-31
Budget Start
2013-09-12
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$152,413
Indirect Cost
$51,220
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chini, Claudia C S; Espindola-Netto, Jair M; Mondal, Gourish et al. (2016) SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Clin Cancer Res 22:2496-507
Murphy, Stephen J; Hart, Steven N; Halling, Geoffrey C et al. (2016) Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. Cancer Res 76:749-61
Chaiteerakij, Roongruedee; Petersen, Gloria M; Bamlet, William R et al. (2016) Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. J Clin Oncol 34:1898-904
Cao, H; Eppinga, R D; Razidlo, G L et al. (2016) Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process. Oncogene 35:1099-110
Hu, Chunling; Hart, Steven N; Bamlet, William R et al. (2016) Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev 25:207-11
McWilliams, Robert R; Maisonneuve, Patrick; Bamlet, William R et al. (2016) Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas 45:311-6
Carr, Ryan M; Fernandez-Zapico, Martin E (2016) Pancreatic cancer microenvironment, to target or not to target? EMBO Mol Med 8:80-2
Wang, Jianbo; Galvao, Joana; Beach, Krista M et al. (2016) Novel Roles and Mechanism for Krüppel-like Factor 16 (KLF16) Regulation of Neurite Outgrowth and Ephrin Receptor A5 (EphA5) Expression in Retinal Ganglion Cells. J Biol Chem 291:18084-95
Lopez, Angelica P; Kugelman, Jeffrey R; Garcia-Rivera, Jose et al. (2016) The Structure-Specific Recognition Protein 1 Associates with Lens Epithelium-Derived Growth Factor Proteins and Modulates HIV-1 Replication. J Mol Biol 428:2814-31
Lakshminarayanan, Vani; Supekar, Nitin T; Wei, Jie et al. (2016) MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. PLoS One 11:e0145920

Showing the most recent 10 out of 242 publications